CathRx sells first product to Europe
Wednesday, 17 September, 2008
CathRx [ASX: CXD] has secured the first sales of its diagnostic modular heart catheters to its UK distributor, in the company's first ever sale to Europe.
Cardiac catheters are minimally invasive tools widely used by specialist cardiologists to help diagnose and treat different types of cardiac arrhythmias.
The global market for cardiac catheters is predicted to be around $1.25 billion, with the European market alone worth $333.2 million.
CathRx plans to offer a progressively-expanding 'toolbox' of heart surgery tools to the European market in the next three quarters.
Multiple myeloma treatment reprograms patients' own immune cells
An Australian and Victorian Government funding agreement has allowed eligible Australians with...
Could 'fusion proteins' reduce errors in a promising gene-editing tool?
Gene-editing tool CRISPR-Cas9 is used, among many things, to engineer new cancer immunotherapies....
Cancer research and clinical trials at the core of new centre
The Australian Cancer Research Foundation Centre for Dynamic Immuno-Oncology (CDIO) has been...
